Goldman Sachs’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.7M | Buy |
414,220
+138,588
| +50% | +$7.31M | ﹤0.01% | 2448 |
|
|
2025
Q4 | $14.5M | Buy |
275,632
+42,090
| +18% | +$2.52M | ﹤0.01% | 2695 |
|
|
2025
Q3 | $15.1M | Buy |
233,542
+12,942
| +6% | +$743K | ﹤0.01% | 2543 |
|
|
2025
Q2 | $10.7M | Buy |
220,600
+73,272
| +50% | +$2.84M | ﹤0.01% | 2698 |
|
|
2025
Q1 | $5.01M | Sell |
147,328
-49,946
| -25% | -$2.12M | ﹤0.01% | 3347 |
|
|
2024
Q4 | $7.76M | Sell |
197,274
-12,566
| -6% | -$593K | ﹤0.01% | 3031 |
|
|
2024
Q3 | $9.86M | Sell |
209,840
-55,507
| -21% | -$2.82M | ﹤0.01% | 2748 |
|
|
2024
Q2 | $14.3M | Buy |
265,347
+132,650
| +100% | +$7.67M | ﹤0.01% | 2166 |
|
|
2024
Q1 | $9.04M | Sell |
132,697
-54,923
| -29% | -$3.93M | ﹤0.01% | 2557 |
|
|
2023
Q4 | $11.7M | Buy |
187,620
+63,575
| +51% | +$3.51M | ﹤0.01% | 2382 |
|
|
2023
Q3 | $5.63M | Sell |
124,045
-13,440
| -10% | -$694K | ﹤0.01% | 2875 |
|
|
2023
Q2 | $7.72M | Sell |
137,485
-99,969
| -42% | -$5.67M | ﹤0.01% | 2699 |
|
|
2023
Q1 | $10.7M | Sell |
237,454
-259,779
| -52% | -$12.6M | ﹤0.01% | 2355 |
|
|
2022
Q4 | $20.2M | Sell |
497,233
-248,673
| -33% | -$13.2M | 0.01% | 1948 |
|
|
2022
Q3 | $48.7M | Buy |
745,906
+250,700
| +51% | +$18.2M | 0.01% | 1134 |
|
|
2022
Q2 | $30.1M | Buy |
495,206
+378,609
| +325% | +$22.3M | 0.01% | 1554 |
|
|
2022
Q1 | $7.32M | Sell |
116,597
-37,589
| -24% | -$2.36M | ﹤0.01% | 2996 |
|
|
2021
Q4 | $11.7M | Sell |
154,186
-173,896
| -53% | -$15.2M | ﹤0.01% | 2616 |
|
|
2021
Q3 | $36.7M | Buy |
328,082
+251,401
| +328% | +$31.6M | 0.01% | 1526 |
|
|
2021
Q2 | $12.4M | Sell |
76,681
-23,692
| -24% | -$2.88M | ﹤0.01% | 2488 |
|
|
2021
Q1 | $12.2M | Sell |
100,373
-15,617
| -13% | -$2.36M | ﹤0.01% | 2379 |
|
|
2020
Q4 | $17.8M | Buy |
115,990
+39,063
| +51% | +$4.62M | ﹤0.01% | 1960 |
|
|
2020
Q3 | $6.43M | Sell |
76,927
-33,131
| -30% | -$2.94M | ﹤0.01% | 2709 |
|
|
2020
Q2 | $8.09M | Buy |
110,058
+5,657
| +5% | +$331K | ﹤0.01% | 2426 |
|
|
2020
Q1 | $4.43M | Sell |
104,401
-25,561
| -20% | -$1.32M | ﹤0.01% | 2734 |
|
|
2019
Q4 | $7.92M | Buy |
129,962
+73,934
| +132% | +$4.04M | ﹤0.01% | 2611 |
|
|
2019
Q3 | $2.3M | Buy |
56,028
+5,175
| +10% | +$247K | ﹤0.01% | 3441 |
|
|
2019
Q2 | $2.4M | Buy |
50,853
+9,388
| +23% | +$375K | ﹤0.01% | 3413 |
|
|
2019
Q1 | $1.48M | Sell |
41,465
-10,214
| -20% | -$353K | ﹤0.01% | 3824 |
|
|
2018
Q4 | $1.48M | Buy |
51,679
+2,029
| +4% | +$70.5K | ﹤0.01% | 3724 |
|
|
2018
Q3 | $2.2M | Sell |
49,650
-2,428
| -5% | -$127K | ﹤0.01% | 3532 |
|
|
2018
Q2 | $3.06M | Buy |
52,078
+24,516
| +89% | +$1.4M | ﹤0.01% | 3310 |
|
|
2018
Q1 | $1.26M | Buy |
27,562
+4,890
| +22% | +$202K | ﹤0.01% | 3906 |
|
|
2017
Q4 | $532K | Buy |
+22,672
| New | +$431K | ﹤0.01% | 4777 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Goldman Sachs's CRSP Position: Q1 2026 in Review
Goldman Sachs increased its CRISPR Therapeutics (CRSP) stake by 50% in Q1 2026, buying an estimated $7.31M and bringing the position to 414,220 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2448.
Goldman Sachs first reported a position in CRSP in Q4 2017 and has held it in 34 quarters since. The position peaked at $48.7M in Q3 2022. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Goldman Sachs held 414,220 shares of CRISPR Therapeutics worth $19.7M as of Q1 2026.
- Goldman Sachs bought 138,588 CRISPR Therapeutics shares in Q1 2026, an estimated $7.31M.
- CRISPR Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2448 holding.
- Goldman Sachs first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 34 quarters since.
- Goldman Sachs's CRISPR Therapeutics position peaked at $48.7M in Q3 2022.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.